Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shampa De

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Archives of Histology and Cytology|February 16, 2006
Krox-20 gene expression: influencing hindbrain-craniofacial developmental interactionsShampa De, Jack E Turman
International Journal of Food Sciences and Nutrition|July 9, 2008
Antioxidant activity and polyphenol content of green tea flavan-3-ols and oligomeric proanthocyanidinsAbdul L Molan, Shampa De, Lucy Meagher
Folia Parasitologica|April 28, 2009
Effect of pine bark (Pinus radiata) extracts on sporulation of coccidian oocystsAbdul Lateef Molan, Zhuojian Liu, Shampa De
Journal of Chemical Neuroanatomy|April 23, 2003
The ontogeny of Krox-20 expression in brainstem and cerebellar neuronsShampa De, Charles F Shuler, Jack E Turman
Developmental Neuroscience|May 12, 2005
Mesencephalic trigeminal nucleus development is dependent on Krox-20 expressionShampa De, Anh Quan Nguyen, Charles F Shuler, et al.
Synapse (New York, N.Y.)|April 23, 2004
Developmental regulation of connexins 26, 32, 36, and 43 in trigeminal neuronsShiho Honma, Shampa De, Daniel Li, et al.
The Patient|March 27, 2015
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week TrialJason Brunetta, Santiago Moreno Guillén, Andrea Antinori, et al.
AIDS Care|October 22, 2015
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatmentEd L Wilkins, Calvin J Cohen, Benoit Trottier, et al.
AIDS (London, England)|February 11, 2014
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCalvin Cohen, David Wohl, Jose R Arribas, et al.
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Archives of Histology and Cytology|February 16, 2006
Krox-20 gene expression: influencing hindbrain-craniofacial developmental interactionsShampa De, Jack E Turman
International Journal of Food Sciences and Nutrition|July 9, 2008
Antioxidant activity and polyphenol content of green tea flavan-3-ols and oligomeric proanthocyanidinsAbdul L Molan, Shampa De, Lucy Meagher
Folia Parasitologica|April 28, 2009
Effect of pine bark (Pinus radiata) extracts on sporulation of coccidian oocystsAbdul Lateef Molan, Zhuojian Liu, Shampa De
Journal of Chemical Neuroanatomy|April 23, 2003
The ontogeny of Krox-20 expression in brainstem and cerebellar neuronsShampa De, Charles F Shuler, Jack E Turman
Developmental Neuroscience|May 12, 2005
Mesencephalic trigeminal nucleus development is dependent on Krox-20 expressionShampa De, Anh Quan Nguyen, Charles F Shuler, et al.
Synapse (New York, N.Y.)|April 23, 2004
Developmental regulation of connexins 26, 32, 36, and 43 in trigeminal neuronsShiho Honma, Shampa De, Daniel Li, et al.
The Patient|March 27, 2015
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week TrialJason Brunetta, Santiago Moreno Guillén, Andrea Antinori, et al.
AIDS Care|October 22, 2015
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatmentEd L Wilkins, Calvin J Cohen, Benoit Trottier, et al.
AIDS (London, England)|February 11, 2014
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCalvin Cohen, David Wohl, Jose R Arribas, et al.
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
Pageof 2